This difference in activity of camizestrant and fulvestrant in patients with detectable ESR1m and ESR1wt is being explored in the ongoing Phase 2 SERENA-2 trial (NCT04214288), comparing the efficacy of camizestrant versus fulvestrant in women with ER+/HER2– advanced breast cancer. Here, ERBB2 is linked to breast carcinoma.